Kolexia
Repesse Yohann Biologie médicale
Repesse Yohann
Biologie médicale
Hôpital Côte de Nacre
Caen, France
118 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Hémophilie A Maladies de von Willebrand Hémorragie Thrombose Hémophilie B Troubles hémorragiques Angiodysplasie Hypertension portale Cirrhose alcoolique

Collaborateurs

Voir plus
Borel-Derlon Annie
Borel-Derlon Annie
Hôpital Côte de Nacre, Caen, France
Harroche-Angel Annie
Harroche-Angel Annie
Hôpital Necker Enfants Malades, Paris, France
Lebreton Aurelien
Lebreton Aurelien
Hôpital Estaing, Clermont-Ferrand, France
D'Oiron Roseline
D'Oiron Roseline
Hôpital Bicêtre, Le Kremlin-Bicêtre, France

Industries

Voir plus
LFB
37 collaboration(s)
Dernière en 2023
Sobi
34 collaboration(s)
Dernière en 2023
CSL Behring
9 collaboration(s)
Dernière en 2021
Takeda Pharmaceutical
6 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
PHILEOS: Haemophilia and Bone Loss PHILEOS Study
Essai Clinique (CHU Saint-Étienne)   29 décembre 2023
Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): A multicentric French national observational cross-sectional study based on the FranceCoag registry.
Haemophilia : the official journal of the World Federation of Hemophilia   12 août 2023
Hémophilie
HAS Publications   20 juin 2023
Symposium Roche-Chugai - CFH 2023 en 5 minutes
Youtube @ Roche France   16 juin 2023
SENIORHEMO: Objective and Perceived Health Status of Elderly People With Moderate or Severe Haemophilia in France: an Ancillary Study of the FranceCoag Registry
Essai Clinique (Assistance publique - Hôpitaux de Marseille)   07 juin 2023
EMICARE: Value of Emicizumab Monitoring With UPLC-MS/MS for Bleeding Risk Prediction in Severe Hemophilia A
Essai Clinique (CHU Lille)   09 février 2023
PO068 FINAL DATA FROM B-SURE, A FRENCH MULTICENTRE STUDY IN PATIENTS WITH HAEMOPHILIA B, EVALUATING REAL-WORLD USAGE AND EFFECTIVENESS OF RECOMBINANT FACTOR IX FC (RFIXFC)
16th Annual Congress of European Association for Haemophilia and Allied Disorders 2023, 7–10 February 2023, Manchester   05 février 2023
PO080 FRENCH REAL-WORD DATA ON RIX-FP PROPHYLAXIS USE IN PATIENTS WITH HAEMOPHILIA B
16th Annual Congress of European Association for Haemophilia and Allied Disorders 2023, 7–10 February 2023, Manchester   05 février 2023
PO102 A FRENCH REAL-WORLD EVIDENCE STUDY EVALUATING THE EFFICACY, SAFETY AND PHARMACOKINETIC PARAMETERS OF RVIII-SINGLECHAIN IN PATIENTS WITH HEMOPHILIA A RECEIVING PROPHYLAXIS
16th Annual Congress of European Association for Haemophilia and Allied Disorders 2023, 7–10 February 2023, Manchester   05 février 2023
PO221 TREATMENT WITH A PLASMA-DERIVED VON WILLEBRAND FACTOR (VWF) ALMOST DEVOID OF FACTOR VIII IN PAEDIATRIC PATIENTS WITH VON WILLEBRAND DISEASE (VWD): A POOLED ANALYSIS
16th Annual Congress of European Association for Haemophilia and Allied Disorders 2023, 7–10 February 2023, Manchester   05 février 2023